OXNARD, Calif., Jan. 04, 2018 -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced the launch of their new brand initiative, inspired by the company’s mission to support patient needs for better delivery of medication.
“Our new branding offers an opportunity to elevate awareness around the challenges patients experience with traditional drug delivery methods, such as pills and injections and to highlight CURE’s solutions,” said Robert Davidson, CEO of CURE Pharmaceutical. “Our updated mission of ‘we improve people’s lives by redefining how medicines are delivered and experienced’ underscores our comittment to patients.”
CURE’s proprietary CUREfilm™ technology platform optimizes drug delivery for better patient outcomes and experiences. CUREfilm™ can be given orally, buccally, sublingually or transdermally, delivering up to 300mg of one or more active ingredients in a single dose. Formulated as a film, actives are absorbed faster, without the need for water or swallowing, and can bypass the GI tract, thereby reducing GI irritation.
As much as 40 percent of the population struggle to swallow pills, and when they do, can have gastrointestinal irritation and are often slow to take effect causing patients to suffer. For drugs that cannot be delivered orally, patients rely on injections and endure the associated pain and inconvenience. It’s time to take a new approach.
To better reflect the company’s emphasis on the patient experience, and to underscore its growth and advancement in pharmaceutical delivery innovation, CURE is introducing a new logo. The logo integrates the letter “C” within a circular motion, representing CURE's 360-degree commitment to patient vitality, and its mission to make a person's life as whole as can be. The transparent layers harken to the CUREfilm™ technology, and further represent the many layers of care each of us needs.
Additional brand enhancements include a new graphic style that embodies transparency, precision, simplicity and aesthetic appeal; a completely redesigned website; and a reinvigorated presence in social media.
About CURE Pharmaceutical
CURE Pharmaceutical is a fully integrated life science company committed to improving drug efficacy, safety and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has an industry leading full-service cGMP manufacturing facility and is a preeminent developer and manufacturer of a patented and proprietary delivery system (CureFilm™), the most advanced oral thin film on the market today. CURE has developed an array of products in cutting-edge delivery platforms and partners with leading pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel and Germany, among other markets. The Company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com.
Forward-looking statements
This press release contains forward-looking statements, which are subject to risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.
Public Relations Contact
Andrew Hard
Chief Executive Officer
CMW Media
[email protected]
P. +1888 829-0070
www.cmwmedia.com


ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
How Marco Pharma International Preserves German Homeopathic Traditions in America
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 



